Alzheimer Disease

Data indicate that consumption of 7 or more units of alcohol per week is associated with higher iron levels in the brain, which has been linked to Alzheimer and Parkinson diseases.

Brexpiprazole is indicated as an adjunctive therapy to antidepressants in adults with major depressive disorder and as a treatment in adults with schizophrenia.

Statistics indicate possible benefit of home-based palliative care interventions, according to study results from the Indiana University School of Medicine and the Regenstrief Institute.

Conditions such as high blood pressure, diabetes, and obesity may have a significant impact on the likelihood of developing cognitive decline, dementia, and Alzheimer disease.

Phase 3 trial results also indicate that Alzheimer disease clinical decline was reduced in participants who had plasma p-tau181 reduction at 78 weeks.

Corium’s Adlarity system lowers the likelihood of adverse gastrointestinal (GI) events that are normally associated with the oral medication.

Using a transgenic mouse model of Alzheimer’s disease, scientists demonstrate a definitive connection with oxidative brain damage.

Tau protein, plaque, and brain waves maybe the solutions to treating the progressive condition.

When using a therapy to clear the senescent cells, disease progression and cell death were stopped, according to the study.

Study results show that clonal hematopoiesis of indeterminate potential is associated with a lower likelihood of developing AD.

Although the test does not definitively diagnose problems such as Alzheimer disease, it helps physicians get a baseline of their patients’ cognitive functioning.

Ten quiz questions to assess your knowledge on common symptoms and treatments for Alzheimer disease.

Investigators have developed an antibody-based treatment for Alzheimer disease, as well as a protein-based vaccine.

The report also describes the benefits of interventions at the family, individual, institutional, organizational, and policy levels and differentiates AD from other types of dementia.

It is an FDA-approved-agent agnostic approach to gathering routine clinical practice data and outcomes for sharing and transparency.

A pharmacist can offer up to date knowledge on the clinical evidence behind new drugs, serving as a source of guidance for patients amongst the controversy with aducanumab and other new medications for Alzheimer disease.

Aducanumab-avwa is a monoclonal antibody that is the first treatment of its class designed to target the amyloid β protein, a biomarker of Alzheimer disease and other dementias.

Patients with senile dementia who have silent epileptic activity show improvement when taking this medication.

The National Institutes of Health grants each entity $14.8 million in funding over the course of 5 years to conduct research into the progressive disease.

The FDA's green light for the Alzheimer medication is worrisome, as clinical trials proved inconclusive.

It is the responsibility of the pharmacist to remain informed of all existing and new drugs for the treatment of Alzheimer disease, especially because novel and investigational drugs may target the pathophysiology of the disease.